Established in 2008, Neuronix develops new methods for modifying the course of treatment for Alzheimer’s Disease (AD) and offers hope and the potential for long-term improvement in the quality of life of patients. Led by a highly motivated management team and supported by an Advisory Board of key opinion leaders in the field, Neuronix’s neuroAD solution is currently undergoing a multi-site clinical study in the United States and is commercially available in clinics in Europe and Israel.
Restore cognitive function in mild to moderate Alzheimer’s Disease
The neuroAD system is based on the company’s core Non Invasive Cortical Enhancer (NICE™) technology and CE-marked for the treatment of mild to moderate Alzheimer’s Disease. This patented technology uses Magnetic Stimulation, concurrently interlaced with Cognitive Training and directed at specific brain regions affected by Alzheimer’s Disease. This combination induces LTP (Long-Term Potentiation), which is associated with learning and memory processes. Results have indicated measurable cognitive improvement, after just a few weeks of treatment, which has shown to last for up to one year.
Peer-reviewed clinical data
Clinical trials performed at the Harvard Medical School and in Israel, showed statistically significant clinical results compared with placebo. neuroAD is CE-marked for commercial use in Europe for the treatment of Alzheimer patients. neuroAD is currently undergoing a multi-center study in the U.S. for FDA approval.
Neuronix is a privately-held company with headquarters in Israel.